Sec Form 4 Filing - Gibson Christopher @ RECURSION PHARMACEUTICALS, INC. - 2022-04-14

Insider filing report for Changes in Beneficial Ownership
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person
Gibson Christopher
2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X __ Director _____ 10% Owner
X __ Officer (give title below) _____ Other (specify below)
Chief Executive Officer
(Last) (First) (Middle)
C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET
3. Date of Earliest Transaction (MM/DD/YY)
04/14/2022
(Street)
SALT LAKE CITY, UT84101
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
__ X __ Form filed by One Reporting Person
_____ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Class A Common Stock 04/14/2022 M( 1 ) 44,010 A $ 2.48 384,134 D
Class A Common Stock 04/14/2022 S( 1 ) 16,017 D $ 7.6162( 2 ) 368,117 D
Class A Common Stock 04/14/2022 C( 1 )( 3 ) 18,500 A $ 0( 4 ) 386,617 D
Class A Common Stock 04/14/2022 S( 1 ) 18,500 D $ 7.5067( 5 ) 368,117 D
Class A Common Stock 04/14/2022 C( 1 )( 3 ) 500 A $ 0( 4 ) 500 I by LAHWRAN-3 LLC
Class A Common Stock 04/14/2022 S( 1 ) 500 D $ 7.4998( 6 ) 0 I by LAHWRAN-3 LLC
Class A Common Stock 04/14/2022 C( 1 )( 3 ) 1,000 A $ 0( 4 ) 1,000 I by LAHWRAN-4 LLC
Class A Common Stock 04/14/2022 S( 1 ) 1,000 D $ 7.5051( 6 ) 0 I by LAHWRAN-4 LLC
Class A Common Stock 04/14/2022 C( 1 )( 3 ) 1,000 A $ 0( 4 ) 1,000 I by Gibson Family Trust
Class A Common Stock 04/14/2022 S( 1 ) 1,000 D $ 7.5125( 6 ) 0 I by Gibson Family Trust
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Class B Common Stock $ 0( 4 ) 04/14/2022 C( 1 )( 3 ) 18,500 ( 4 ) ( 4 ) Class A Common Stock 6,948,334 $ 0( 4 ) 6,948,334 D
Stock Option (Right to Buy) $ 11.4 ( 7 ) 02/04/2032 Class A Common Stock 416,350 416,350 D
Stock Option (Right to Buy) $ 11.4 02/04/2022 02/04/2032 Class A Common Stock 5,436 5,436 D
Stock Option (Right to Buy) $ 2.48 04/14/2022 M( 1 ) 44,010 ( 8 ) 12/30/2030 Class A Common Stock 1,251,304 $ 0 1,251,304 D
Class B Common Stock $ 0( 4 ) 04/14/2022 C( 1 )( 3 ) 500 ( 4 ) ( 4 ) Class A Common Stock 547,500 $ 0( 4 ) 547,500 I by LAHWRAN-3 LLC( 9 )
Class B Common Stock $ 0( 4 ) 04/14/2022 C( 1 )( 3 ) 1,000 ( 4 ) ( 4 ) Class A Common Stock 545,000 $ 0( 4 ) 545,000 I by LAHWRAN-4 LLC( 10 )
Class B Common Stock $ 0( 4 ) 04/14/2022 C( 1 )( 3 ) 1,000 ( 4 ) ( 4 ) Class A Common Stock 141,875 $ 0( 4 ) 141,875 I by Gibson Family Trust( 11 )
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Gibson Christopher
C/O RECURSION PHARMACEUTICALS
41 S. RIO GRANDE STREET
SALT LAKE CITY, UT84101
X Chief Executive Officer
Signatures
/s/ Jonathan Golightly, attorney-in-fact 04/18/2022
Signature of Reporting Person Date
Explanation of Responses:
( 1 )Transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
( 2 )This transaction was executed in multiple trades at prices ranging from $7.61 to $7.65. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
( 3 )Represents the conversion of Class B Common Stock into Class A Common Stock.
( 4 )Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
( 5 )This transaction was executed in multiple trades at prices ranging from $7.35 to $7.64. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
( 6 )This transaction was executed in multiple trades at prices ranging from $7.36 to $7.60. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
( 7 )The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
( 8 )The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the option on January 31, 2021, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
( 9 )The shares are held by LAHWRAN-3 LLC, of which the Reporting Person is a member and a manager.
( 10 )The shares are held by LAHWRAN-4 LLC, of which the Reporting Person is a member and a manager.
( 11 )The shares are held by the Gibson Family Trust, of which the Reporting Person serves as Trustee.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.